Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 10, 2012 09:49 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Reports Second Quarter 2012 Financial Results

Completion of $105 Million IPO Five Therapeutic Candidates in the Clinic, Each Planned to be Developed With a Companion Diagnostic From Proprietary Network Biology Platform Over 15 Clinical...
August 01, 2012 09:00 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Announces Timing of Second Quarter 2012 Investor Conference Call

CAMBRIDGE, Mass., Aug. 1, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Second Quarter 2012 Investor Conference Call and webcast...
July 23, 2012 17:14 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals, Inc. [MACK] to Ring The NASDAQ Stock Market Opening Bell on Tuesday, July 24, 2012

Biotech company has five novel therapeutic oncology candidates in clinical development MM-398 in Phase 3 clinical study for patients with metastatic pancreatic cancer who have previously failed...
July 16, 2012 16:33 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Announces the Addition of Former Deloitte Global CEO James H. Quigley to Its Board of Directors

CAMBRIDGE, Mass., July 16, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the election of James Quigley, CEO emeritus of Deloitte Touche Tohmatsu, Limited (the...
July 09, 2012 17:30 ET | Source: Merrimack Pharmaceuticals

William M. McClements Joins Merrimack Pharmaceuticals as Senior Vice President of Corporate Operations

CAMBRIDGE, Mass., July 9, 2012 (GLOBE NEWSWIRE) -- William M. McClements, a former executive at the Monitor Group, has joined Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) as Senior Vice President of...
June 28, 2012 16:52 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals and Cancer Treatment Centers of America(R) Partner in Multifaceted Collaboration to Advance Translational Research and Individualized Treatment

CAMBRIDGE, Mass., June 28, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) and the Cancer Treatment Centers of America® (CTCA) announced today that they have formed a...
June 27, 2012 17:06 ET | Source: Merrimack Pharmaceuticals

Merrimack Announces Expansion of Phase 3 NAPOLI-1 Study of MM-398 in Late Stage Pancreatic Cancer

Expansion to Include MM-398 in Combination With 5-Fluorouracil and Leucovorin Additional Arm Explores Broader Usage of MM-398 in a Setting Where Combination Therapy is Becoming More...
June 26, 2012 16:59 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals to Present at the 2012 American Association for Cancer Research Chemical Systems Biology Conference

Two Abstracts Selected for Oral Presentation Three Posters to be Presented, Each on Different Examples of Applying the Network Biology Approach to Therapeutic Development CAMBRIDGE, Mass., June...
June 20, 2012 16:30 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Set to Join Russell 3000 Index

CAMBRIDGE, Mass., June 20, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) is set to join the broad-market Russell 3000® Index when Russell Investments reconstitutes its...
June 18, 2012 16:09 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Announces the Addition of Cancer Research Pioneer John Mendelsohn, M.D. to Its Board of Directors

CAMBRIDGE, Mass., June 18, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the election of John Mendelsohn, M.D., past president of The University of Texas MD...